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To document clinical outcomes and women’s experiences following the introduction of
mifepristone into South African public sector second-trimester medical abortion services,
and compare with historic cohorts receiving misoprostol-only.
Methods
Repeated cross-sectional observational studies documented service delivery and experi-
ences of women undergoing second-trimester medical abortion in public sector hospitals in
the Western Cape, South Africa. Women recruited to the study in 2008 (n = 84) and 2010 (n
= 58) received misoprostol only. Those recruited in 2014 (n = 208) received mifepristone
and misoprostol. Consenting women were interviewed during hospitalization by study field-
workers with respect to socio-demographic information, reproductive history, and their
experiences with the abortion. Clinical details were extracted from medical charts following
discharge. Telephone follow-up interviews to record delayed complications were conducted
2–4 weeks after discharge for the 2014 cohort.
Results
The 2014 cohort received 200 mg mifepristone, which was self-administered 24–48 hours
prior to admission. For all cohorts, following hospital admission, initial misoprostol doses
were generally administered vaginally: 800 mcg in the 2014 cohort and 600 mcg in the
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earlier cohorts. Women received subsequent doses of misoprostol 400 mcg orally every
3–4 hours until fetal expulsion. Thereafter, uterine evacuation of placental tissue was per-
formed as needed. With one exception, all women in all cohorts expelled the fetus. Median
time-to-fetal expulsion was reduced to 8.0 hours from 14.5 hours (p<0.001) in the mifepris-
tone compared to the 2010 misoprostol-only cohort (time of fetal expulsion was not
recorded in 2008). Uterine evacuation of placental tissue using curettage or vacuum aspira-
tion was more often performed (76% vs. 58%, p<0.001) for those receiving mifepristone;
major complication rates were unchanged. Hospitalization duration and extreme pain levels
were reduced (p<0.001), but side effects of medication were similar or more common for the
mifepristone cohort. Overall satisfaction remained unchanged (95% vs. 91%), while other
acceptability measures were higher (p<0.001) for the mifepristone compared to the miso-
prostol-only cohorts.
Conclusion
The introduction of a combined mifepristone-misoprostol regimen into public sector second-
trimester medical abortion services in South Africa has been successful with shorter time-
to-abortion events, less extreme pain and greater acceptability for women. High rates of
uterine evacuation for placental tissue need to be addressed.
Introduction
Accessible and effective provision of second-trimester abortion is particularly important in set-
tings where a high proportion of women seek abortion in the second trimester, as is common
in low- and middle-income countries (LMICs) [1, 2]. South Africa’s abortion legislation of
1996 allows for abortion between 12 and 20 weeks for several indications, including on socio-
economic grounds [3]. In the Western Cape Province of South Africa, 28% of all abortions are
performed in the second trimester, which is higher than reported for the United States, United
Kingdom, Nepal and the Russian Federation [4–8], although lower than in some parts of India
[9, 10].
Both surgical and medical methods for second-trimester abortion are considered safe and
effective when performed by skilled providers, and major complications are rare events [11–
13]. However, shortages of physicians trained in dilation and evacuation (D&E) are a common
problem, and medical methods using recommended regimens are increasingly used in
resource-constrained settings [1, 2, 14, 15]. Randomized controlled trials (RCTs) comparing
the combined mifepristone-misoprostol regimen to misoprostol used alone in the second tri-
mester have consistently shown improvements in efficacy and time to abortion [14, 16–18].
Observational studies have documented similar outcomes following introduction of the com-
bined regimen into services [19–24]. However, even in LMICs where mifepristone combined
with misoprostol is standard of care for first-trimester abortion, this regimen has been less
commonly used for later procedures. Possible reasons include limited recognition of its greater
efficacy over the misoprostol-only regimen for second trimester procedures, and that compara-
tively less effort has been directed to advocating for the use of mifepristone than for first tri-
mester procedures, as the procedure take places in hospital settings [14]. In addition, in South
Africa, mifepristone is not registered for use in the second trimester, and it was only added to
the national essential drug list for this indication in 2012.
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PLOS ONE | DOI:10.1371/journal.pone.0161843 September 1, 2016 2 / 14
Competing Interests: The authors have declared
that no competing interests exist.
Medical methods for abortion have been shown to be acceptable to women in many settings,
both for first- and second-trimester procedures, as well as for managing incomplete abortion
[11, 17, 25–28]. Factors reducing acceptability of first-trimester medical abortion with mifep-
ristone include treatment failure, extreme pain and bleeding, inconvenience and anxiety [26–
29]. In contrast, for second-trimester medical abortion, prolonged induction duration and high
levels of pain reduce women’s acceptability and satisfaction with their procedure [17, 30].
With a shortage of physicians in the South African public sector who are skilled in D&E and
willing to provide the service [31], medical abortion is generally the standard of care in the sec-
ond trimester. In South Africa prior to 2013, second-trimester medical abortion was provided
using a regimen of misoprostol only.
Previous research among women undergoing second-trimester abortion in South Africa
using the misoprostol-only regimen reported safe abortion provision; however, the study
reported delays in accessing care, and prolonged hospitalization beyond 2 days in many cases
[11]. The mifepristone-misoprostol regimen for medical abortion was introduced into several
public sector hospitals in the Western Cape Province in 2013 and 2014.
Implementation of new second-trimester abortion services into public sector teaching hos-
pitals in LMICS s can be challenging as limited capacity, high patient-to-staff ratios, extensive
referral areas, complicated referral pathways, high rates of staff rotation are commonplace [1,
7, 11, 32–34]. We aimed to add to the limited literature on second-trimester abortion from
such settings by describing clinical outcomes and women’s experiences following the introduc-
tion of mifepristone into medical abortion services and comparing these to previous cohorts
receiving misoprostol only.
Methods
Study design and participants
The historic cohorts receiving misoprostol-only were recruited from February through July
2008 and April through August 2010 at Obstetric and Gynecology departments of two public
sector teaching hospitals (Hospitals A & B, Fig 1) in the Western Cape providing medical abor-
tion. Both hospitals are general specialist hospitals with 24-hour availability of surgical, anes-
thesia and blood transfusion services. Hospital A is in an urban and Hospital B in a semi-rural
location, both with extensive referral areas. These two cohorts (2008 and 2010) were combined
into a single misoprostol-only group for this analysis. The third cohort (referred to as the
mifepristone group) received mifepristone for self-administration at home followed by admis-
sion for misoprostol and was recruited from October 2013 through June 2014, also at two pub-
lic sector hospitals. This combined mifepristone-misoprostol regimen was introduced into a
newly expanded service at Hospital C, an urban, highly specialized facility, and into Hospital B
from the previous 2008/2010 cohorts, with Hospital A switching from medical abortion to a
D&E service (Fig 1). In South Africa, second-trimester medical abortion takes place in second-
ary level hospitals. Hospitals A, B and C were the only facilities in the Western Cape providing
the service. Additional hospitals in the province provide limited D&E services [11]. Ethical
approval for all studies was given by the University of Cape Town Human Research Ethics
Committee and the Allendale Investigational Review Board.
Procedures
In all cohorts, women requesting abortion were referred from primary care facilities with a
confirmed pregnancy and gestational age dating by ultrasound. At study facilities, women
underwent further examination by physicians, received counselling and provided consent for
the procedure, and a booking was arranged for admission to the general gynecology ward.
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Study recruitment and procedures were similar for all cohorts. During the recruitment peri-
ods, within logistical constraints of one fieldworker per facility, all women undergoing medical
abortion were approached for participation. Eligibility criteria included having been assessed
by physicians and deemed medically appropriate for the service, having consented for medical
abortion, being age 18 years or older, pregnant with a gestational age at time of mifepristone
administration between 12 weeks 1 day and 20 weeks 0 days, and able to communicate in
English or isiXhosa. Written informed consent to participate in the study was obtained follow-
ing a confirmed booking for admission or on admission. Trained, experienced study fieldwor-
kers not involved in service provision administered structured face-to-face interviews
recording socio-demographic information, reproductive history, and women’s experience of
the abortion procedure. Questions were standardized and identical for all cohorts. Interviews
were conducted initially after admission and again prior to discharge or within 48 hours there-
after by phone. Investigators abstracted clinical information related to the abortion from hospi-
tal records after discharge. Fieldworkers conducted an additional follow-up telephone
interview 2–4 weeks after discharge to collect information about delayed complications for the
mifepristone group.
Study outcomes
The primary outcome was 24-hour fetal expulsion rate (defined from first misoprostol dose to
fetal expulsion; time of fetal expulsion was not recorded for the 2008 cohort). Other clinical
outcomes included drug administration, time-to-fetal expulsion, rates of uterine evacuation for
placental tissue and time-to-abortion completion (defined as time from first misoprostol dose
to placental expulsion if no evacuation, or completion of evacuation, if done). In addition, hos-
pitalization duration, analgesia, major complications (death, abdominal surgery, hospital read-
mission, hemorrhage requiring transfusion, infection treated with intravenous antibiotics and/
Fig 1. Participant recruitment to 2008, 2010 and 2014 cohorts.
doi:10.1371/journal.pone.0161843.g001
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or seizure) and post-abortion contraception were recorded. Women’s experiences included
presence of side effects (yes/no), and level of pain, overall satisfaction (how would you describe
your overall satisfaction with your abortion?) and acceptability (would you recommend the
method to a friend?) measured on 5-point scales.
Analysis
Data were analyzed using Stata v.13. Data for the 2008 and 2010 misoprostol-only cohorts
were combined to improve statistical power of the historical data. Missing data were not
imputed, and only valid percentages were reported. Descriptive statistics were reported for par-
ticipant characteristics and study outcomes. Five point scales were collapsed to three categories
for analysis, and groups were compared using Chi-squared tests for proportions or Kruskal-
Wallis tests for medians. Kaplan-Meier analyses and log-rank tests were used to compare unad-
justed time-to-fetal expulsion between mifepristone and misoprostol-only groups. To adjust
for confounding and differences in drug administration, hazard ratios (HRs) for time-to-expul-
sion were calculated for exposure to mifepristone, adjusted for significant covariate differences
identified a priori, (age, gestational age, prior vaginal delivery, parity, prior abortion) and strati-
fied by quartiles of total misoprostol dosage. HRs were also calculated for the majority sub-
group of participants receiving their first misoprostol dose via the vaginal route of
administration (PV).
Sample size
The desired sample size was based on fetal expulsion rate, as the more direct measure of abor-
tion effectiveness compared to abortion completion, which is dependent on physician practice
with regard to curettage. Reported fetal expulsion rates within 24 hours range between 93–97%
for the mifepristone-misoprostol regimen [13, 15] and for our misoprostol-only 2010 cohort
was 72% (95% CI: 63%– 81%). To be conservative, we based our sample size calculation on a
90% fetal expulsion rate within 24 hours for the mifepristone-misoprostol group and 81% for
the misoprostol-only group (the upper limit of the 2010 cohort 95% CI). We calculated that a
sample size of 131 participants in the mifepristone cohort would suffice to detect a significant
difference in fetal expulsion rate within 24 hours between the mifepristone and the misopros-
tol-only cohorts using a one-sided 2.5% level test of significance, with a power of 90%. To allow
for analysis of covariate effects, we planned to include 200 women in the mifepristone cohort.
Results
For the 2008 and 2010 misoprostol-only and mifepristone cohorts respectively, 86% (84/97),
62% (58/94) and 85% (208/244) of women screened for participation were enrolled into the
study. Overall, enrolled women constituted 50% (350/700) of all women undergoing medical
abortion at study facilities during the study periods. Participant enrolment for all cohorts,
including reasons for non-participation are shown in Fig 1.
Participant characteristics
Significant differences in participant characteristics between the 2008 and 2010 misoprostol-only
cohorts were gestational age at initiation of abortion (median (interquartile range): 18.1 weeks
(17.6–19.9) and 16.5 weeks (14.9–17.6) respectively; and the proportion reporting prior abor-
tions (7% [5/74] in 2008 compared to none in 2010). Participant characteristics for the combined
2008/2010 misoprostol group and the mifepristone group are shown in Table 1. There were no
significant differences between the combined misoprostol-only group and the mifepristone
Second-Trimester Medical Abortion in South Africa
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group for age, education, formal housing, paid work, home language, parity or prior vaginal
delivery. More participants receiving mifepristone reported prior abortions and median gesta-
tional age on admission was 1 week later than the misoprostol-only group (Table 1).
Drug Administration
All women in the mifepristone cohort were instructed to self-administer 200 mg mifepristone
orally at home, 24–48 hours prior to their booked admission date. Women with gestations
within 1–2 days of the legal limits for medical abortion were given priority bookings, and
admission was arranged in order to manage bed availability. Only 1 participant was admitted
directly following assessment for mifepristone administration in the hospital, as her travel time
home and back would have been excessive. The median and inter-quartile range (IQR) for the
mifepristone-misoprostol interval was 49 hours (IQR 4–53). Intervals were<48 hours for 44%
(91/208) participants and>72 hours for 2% (4/208). All participants reported they took the
mifepristone at home, and none aborted prior to hospital admission.
Following admission, administration of misoprostol was incorporated into the general ward
routine. Misoprostol doses and administration routes are shown in Table 2. Although there
Table 1. Participant characteristics by medication regimen.
Characteristic 2008/2010 misoprostol-only 2014 mifepristone-misoprostol p-value*
Age (years) n = 142 n = 208
18–25 77 (54%) 94 (45%) 0.373
26–35 53 (37%) 92 (44%)
>35 12 (8%) 22 (11%)
High school education n = 129‡ n = 208
Completed Grade 12 62 (48%) 98 (47%) 0.477
Home language n = 138# n = 208
Xhosa 86 (62%) 151 (73%) 0.118
English 26 (19%) 22 (11%)
Afrikaans 17 (12%) 25 (12%)
Other 9 (7%) 10 (5%)
Employment n = 129‡ n = 208
Paid work 50 (39%) 80 (39%) 0.523
Parity n = 142 n = 208
Nulliparous 26 (18%) 41 (20%) 0.428
Prior vaginal delivery n = 129‡ n = 208
95 (74%) 144 (69%) 0.229
Prior abortion n = 129‡ n = 208
5 (4%) 21 (10%) 0.027
Gestational age (weeks)** n = 142 n = 208
12.1–16.0 36 (25%) 30 (14%) <0.001
16.1–18.0 54 (38%) 55 (26%)
18.1–20.0 52 (37%) 123 (59%)
*p-value for chi squared tests of differences between misoprostol-only and mifepristone-misoprostol groups.
‡13 records with missing data
#4 records with missing data.
**Gestational age at abortion commencement.
Date of first misoprostol for 2008 and 2010 cohorts, and date of mifepristone for 2014 cohort.
doi:10.1371/journal.pone.0161843.t001
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was an attempt to standardize the protocol, dosage regimens sometimes differed across facili-
ties, or according to physician preference in certain situations, such as with prior caesarean sec-
tion. Generally, misoprostol-alone cohorts received an initial dose of 600 mcg, with 21% (28/
135) receiving 400 or 200 mcg. Administration routes were mostly vaginal (PV) (84%, 113/
135), with a minority receiving either oral or sublingual administration. Subsequent dosing
was 400 mcg at 3- or 4-hourly intervals. If no expulsion had occurred after 13 doses, following
a rest period, misoprostol was started again. If expulsion did not occur, other prostaglandins
were used. For the combined mifepristone-misoprostol regimen the first misoprostol dose was
generally 800 mcg administered PV, with 24% (49/208) receiving either 400 mcg orally or 600
mcg PV or by the sublingual route. Subsequent dosing was mostly 400 mcg orally, with 7%
(13/208) sublingually, up to 10 doses if needed, sometimes followed by a rest period. The
median total dose of misoprostol and the median number of misoprostol doses were less in the
mifepristone cohort (1600 mcg vs. 1800 mcg; 2 vs. 3, p<0.001).
Clinical outcomes
Fetal expulsion occurred in all participants except one in the 2008 misoprostol-only cohort,
who was transferred to another facility for D&E. Median time-to-fetal expulsion was shorter
(8.0 vs. 14.5 hours; p<0.001), and the proportion with fetal expulsion within 24 hours higher
(93% [194/208] vs. 77% [44/57]; p<0.001) for the mifepristone cohort compared to the miso-
prostol-only 2010 cohort. Kaplan-Meier survival curves and log rank tests for unadjusted time-
to-fetal expulsion demonstrated significantly shortened intervals for the mifepristone cohort
(p<0.001, Fig 2). Hazard ratios for fetal expulsion from Cox proportional models adjusted for
Table 2. Misoprostol dosage regimen.
Misoprostol regimen 2008/2010 misoprostol-only 2014 mifepristone-misoprostol
Dosage of 1st misoprostol n = 135‡ n = 208
200 mcg 2 (1.5%) 0 (0%)
400 mcg 26 (19.3%) 13 (6.3%)
600 mcg 107 (79.3%) 36 (17.3%)
800 mcg 0 (0%) 159 (76.4%)
Route of administration of 1st dose n = 135‡ n = 208
Vaginal 113 (83.7%) 178 (85.6%)
Oral 20 (14.8%) 13 (6.3%)
7Sublingual 2 (1.5%) 17 (8.2%)
Dosage of 2nd misoprostol n = 133‡ n = 191
200 mcg 11 (8.3%) 0 (0%)
400 mcg 120 (90.2%) 179 (93.7%)
600 mcg 2 (1.5%) 12 (6.3%)
800 mcg 0 (0%) 0 (0%)
Route of administration of 2nd dose n = 133‡ n = 191
Vaginal 1 (0.8%) 0 (0%)
Oral 130 (97.7%) 178 (93.2%)
Sublingual 2 (1.5%) 13 (6.8%)
Total misoprostol dosage (mcg) Median (IQR)* 1800 (1400–2400) 1600 (1200–2000)
Number of misoprostol doses Median (IQR)* 4 (4–6) 3 (2–4)
* p<0.001. Kruskal-Wallis test for median differences between misoprostol-only and mifepristone-misoprostol groups.
‡7 records with missing data.
doi:10.1371/journal.pone.0161843.t002
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gestational age, prior abortion and prior vaginal delivery and stratified by quartiles of total
misoprostol dose were significantly higher for the mifepristone group, overall and for the PV
subgroup (p<0.05 for all strata, S1 Table).
Uterine evacuation of placental tissue was performed according to physicians’ judgement,
and there was higher rate of uterine evacuation of placental tissue among the mifepristone
group over the misoprostol-only group (76% [159/208] vs. 58% [82/142]; p<0.001, Table 3).
Methods used were curettage in the 2008/2010 cohorts and vacuum aspiration or curettage for
the mifepristone group. Despite higher evacuation rates, median time-to-abortion completion,
which includes time to completion of uterine evacuation, if performed, was significantly
shorter in the mifepristone group (11.1 vs. 24.8 hours; p<0.001) compared to misoprostol only
and a significantly higher proportion had completed their abortion within 24 hours (88% [177/
208] vs. 46% [62/134]; p<0.001, Table 3).
Duration of hospitalization was significantly shorter for the mifepristone group (77% [161/
208] vs. 44% [62/142] staying one night or less; p<0.001). The rate of major complications was
similar for the two groups (6% [12/208] vs. 8% [11/142]; p = 0.791). Complications included
hemorrhage requiring blood transfusion, infection treated with IV antibiotics and possible sei-
zure (Table 3). All these complications were identified during hospitalization except for one in
Fig 2. Time-to-fetal expulsion (unadjusted) for 2010misoprostol-only (n = 57) andmifepristone groups (n = 208).
doi:10.1371/journal.pone.0161843.g002
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the mifepristone cohort, which was identified at the follow-up call. More women received anal-
gesia in the mifepristone compared to the misoprostol groups (83% [173/208] vs. 44% [63/
142]; p<0.001). Almost all participants in both mifepristone and misoprostol-only groups
(99% [204/208] and 98% 125/127]; p = 0.623) received a family planning method post-abor-
tion. The most common method in both groups was the injectable (67% [139/204] vs. 87%
[111/125]), with a shift towards the implant (introduced into the public sector in 2013) in the
mifepristone group (20% [42/204]).
Women’s experiences
More participants in the mifepristone group experienced nausea (55% [112/205] vs. 22% [29/
129]; p<0.001), vomiting (45% [92/205] vs. 27% [35/129]; p<0.001) and tiredness (76% [155/
203] vs. 56% [72/129]; p<0.001). Other symptoms experienced similarly by both mifepristone
Table 3. Procedure details and clinical outcomes.
Clinical outcomes 2008/2010 misoprostol-only 2014 mifepristone-misoprostol p-value*
Time from 1st dose misoprostol to fetal expulsion n = 57‡ n = 208 <0.001
Median (IQR) (hours) 14.5 (11.5–24.0)‡ 8.0 (6.0–11.9) <0.001
Fetal expulsion <24 hours n = 57‡ n = 208
n (%) 44 (77%)‡ 194 (93%) <0.001
Uterine evacuation performed n = 142 n = 208
n (%) 82 (58%) 159 (76%) <0.001
Time from 1st dose of misoprostol to abortion completion** n = 134# n = 208 <0.001
Median (IQR) (hours) 24.8 (17.8–37.6) 11.1 (8.7–17.0)
Complete abortion <24 hours n = 134# n = 208 <0.001
n (%) 62 (46%) 177 (88%)
Hospitalization n = 142 n = 208
Same day discharge 1 (1%) 0 (0%) <0.001
1 night 62 (43%) 161 (77%)
2 nights 80 (56%) 47 (23%)
Analgesia given n = 142 n = 208
n (%) 63 (44%) 173 (83%) <0.001
Major complications n = 142 n = 208
n (%) 11 (8%) 12 (6%) 0.791
Haemorrhage requiring transfusion 8 (6%) 9 (4%)
Infection treated with IV antibiotics 3 (2%) 2 (1%)
Possible seizure 0 (0%) 1 (<1%)
Received post-abortion family planning n = 127*** n = 206 §
n (%) 125 (98%) 204 (99%) 0.623
Injectable 111 (87%) 139 (67%)
Oral contraceptives 9 (7%) 4 (2%)
Intrauterine device 5 (4%) 19 (9%)
Implant 0 (0%) 42 (20%)
*p-value of Chi-squared tests for differences between misoprostol-only and mifepristone-misoprostol groups.
‡Data only recorded for 2010 cohort, 1 record with missing data.
**Abortion completion defined as either placental expulsion if no surgery or surgery.
#8 records with missing data,
§ 2 records with missing data,
*** 15 records with missing data
doi:10.1371/journal.pone.0161843.t003
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and misoprostol-only groups, respectively, were diarrhea (58% [119/205] vs. 62% [80/129];
p = 0.472), dizziness (41% [85/205] vs. 40% [52/129]; p = 0.835) and headache (35% [72/203]
vs. 37%, [48/129]; p = 0.441). There was no significant linear association between pain levels
and groups (Table 4); however, fewer women in the mifepristone compared to the misoprostol
group experienced extreme pain compared to other levels of pain (13% [26/205 vs. 41% [53/
129]; p<0.001). Trends in overall satisfaction were similar for both group, while more reported
they would recommend the abortion method to a friend in the mifepristone group (Table 4;
p<0.001).
Discussion
Compared to the previous misoprostol-only regimen, the new service regimen reduced time-
to-abortion events and hospitalization. The 93% fetal expulsion rate within 24 hours in our
mifepristone group is slightly lower compared to the 94–98% reported in RCTs and case series
[15, 16, 22–24]. It is possible that the variability of the mifepristone-misoprostol interval in our
study (range; 27–77 hours) contributed to the marginally lower expulsion rate compared to
these studies. In addition, the dosing and route of administration of misoprostol in our 2014
mifepristone group was not wholly consistent with the WHO evidence-based clinical guide-
lines for mifepristone in combination with misoprostol, which advise 800 mcg vaginally, fol-
lowed by 400 mcg vaginally or sublingual, q 3 hrs., and 400mcg vaginally or sublingual,
repeated q 3 hrs. for misoprostol only [35]. This may also have contributed to the slightly lower
24-hour expulsion rates than reported elsewhere. Deviations fromWHO protocol were due to
physician preference in cases with prior caesarean section, and the use of the oral route for the
second misoprostol dose is in accordance with Royal College of Obstetricians and Gynaecolo-
gists (RCOG) guidance, which has been followed in other settings [23].
Other research has reported much lower rates of placental retention for second-trimester
medical abortion with mifepristone [16], and our finding of a higher surgical evacuation rate






Overall pain during abortion experience n = 129 ‡ n = 205#
Extreme pain 53 (41%) 26 (13%) 0.320
High pain 23 (18%) 108 (53%)
Moderate pain 19 (15%) 64 (31%)
Slight pain 14 (11%) 18 (8%)
No pain 20 (16%) 2 (1%)
Overall satisfaction with abortion n = 129 ‡ n = 205#
Very or somewhat satisfied 117 (91%) 195 (95%) 0.127
Neutral 8 (6%) 3 (2%)
Somewhat or very dissatisfied 4 (3%) 7 (3%)
Would recommend the abortion method to a friend who needed one at same
gestational age
n = 129 ‡ n = 205#
Highly or somewhat agree 90 (70%) 183 (89%) <0.001
Neutral 4 (3%) 1 (0.5%)
Somewhat or highly disagree 35 (7%) 21 (10%)
*p-value for chi squared test for trend of linear association between groups and levels of outcome
‡13 records with missing,
#3 records with missing data.
doi:10.1371/journal.pone.0161843.t004
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with the mifepristone regimen is likely to be specific to the service delivery setting. In both
study groups time-to-abortion completion may have been extended due to lack of operating
theatre availability when uterine evacuation was performed, which was facility-dependent. The
high rate of evacuation, especially in the mifepristone group, may be related to the introduction
of the new service in teaching facilities with a high rotation of junior doctors. This may have
also contributed to the shorter time-to-abortion completion in this group. Routine use of evac-
uation varies across settings and institutions [13, 36]; however, it is acknowledged that clinical
experience in assessment of abortion completion and manual assistance with placental expul-
sion is needed to avoid this practice [13]. Further training of health professionals in this regard
has been implemented in our study facilities.
The introduction of self-administration of mifepristone at home prior to admission for sec-
ond-trimester medical abortion allowed for planning for admission while eliminating addi-
tional hospital visits for mifepristone where admission was delayed by more than 48 hours.
Although women’s convenience was not specifically catered to in this study, flexible timing of
admission without requiring mifepristone to be taken on-site gives women time to arrange
their personal affairs, if needed, and we consider it a beneficial service delivery option. Most
women stayed at least one night in hospital as incorporation of abortion care into the general
ward routine delayed women receiving their misoprostol while this study was in progress. To
facilitate same-day discharge, a day ward administering misoprostol immediately at early
morning admission is recommended as the most cost-effective model of service provision for
medical abortion [13, 36]. This was considered feasible in China and Europe [15, 23, 37], and
was recently implemented at hospital C (personal communication, MP, 2015). It is expected
that the new regimen may reduce costs per woman served, which we plan to explore in a future
analysis.
The number of women experiencing hemorrhage requiring transfusion was similar in both
the mifepristone and misoprostol-only groups and (Table 3). The proportion in the mifepris-
tone group (4.3%) was comparable to the 4% rate reported previously for all deliveries in a
South African hospital in 2010 [38], but higher than other studies on second-trimester medical
abortion, which vary from 0.7–3% [16, 23, 24]. The transfusion threshold is context- and pro-
vider-dependent, and most women having transfusions had a documented drop in hemoglobin
with signs and/or symptoms of anemia. Possible reasons for this higher rate of transfusion
could be a high rate of baseline anemia, or the high HIV prevalence; nonetheless, interventions
to reduce transfusion should be explored in future research. For other major complications, of
the 5 cases with infections requiring IV antibiotics, 4 were detected during admission. While
seemingly of different origin, the 1% infection rate in this study is comparable to that (8/1002)
reported elsewhere at 2-week follow-up [23].
In terms of women’s experiences, both the mifepristone and the misoprostol-only groups
reported a high prevalence of common side effects. The greater proportion in the mifepristone
group experiencing nausea, vomiting and tiredness may be due to the higher initial dose of
misoprostol, or possibly to mifepristone. In contrast, this group also reported less extreme pain
levels and more received analgesia than the misoprostol-only cohorts; however, pain levels in
all groups remained high, and more research on pain management is needed to better guide
practice. The improved acceptability in the mifepristone group, despite the higher proportion
who underwent curettage for retained placental tissue, is encouraging. Reduced hospitalization
and less extreme pain may have contributed to a better experience. However, unmeasured dif-
ferences between facilities and over time may also have played a part, and we cannot make con-
clusive statements in this regard from our data.
Limitations of this study are that the majority of participants in the mifepristone cohort
groups were from a different facility from the historic cohorts due to changes in service
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delivery. Study groups were non-randomized. For example, gestational age was different in the
two groups; however, we adjusted for known confounders, including gestational age, in the
proportional hazards analysis (S1 Table). The comparison for time-to-fetal expulsion may
have been underpowered due to the missing data in the 2008 cohort; nonetheless our study
findings were statistically and clinically significant. The participant numbers were unbalanced
between the two centers in all cohorts as Hospital B is a smaller site; however, proportions rela-
tive to the overall caseload for each center were consistent over the three phases of data collec-
tion. In addition, the study extended over six years of service provision, during which
unmeasured confounding factors may have been influenced our findings. We did not conduct
follow-up interviews for either of the misoprostol-only cohorts; however, the chart reviews
were done subsequent to discharge, thus it is unlikely that we have underestimated major com-
plications for this group. There may have been some social desirability bias, however this
would not have differed between the study groups. The initial misoprostol dosages differed
between the study groups, but they were generally consistent with WHO guidance, which rec-
ommends a lower dose for the misoprostol-only second-trimester regimen [35]. To take this
into account, we stratified the proportional hazards analysis according to categories of overall
misoprostol dosage (S1 Table). The misoprostol dosages sometimes differed from recom-
mended regimens; however, in this observational study we aimed to observe real-world out-
comes after implementing this new service. Finally, our findings are specific to the South
African context where second-trimester medical abortion is performed in secondary level hos-
pitals and may not be generalizable to other settings.
Conclusions
This study reports clinical and acceptability improvements during introduction of a mifepris-
tone-misoprostol regimen for medical abortion at 12–20 weeks gestational age at busy public
sector hospitals in South Africa. Specific aspects that were successful included self-administra-
tion at home of mifepristone which allowed for admission planning, shortened procedure
times, reduced hospitalization which increased the capacity of facilities to serve more women
compared to previously, and increased acceptability.
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